Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Invesco Ltd.

Invesco Ltd. raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,064,529 shares of the company's stock after purchasing an additional 355,581 shares during the quarter. Invesco Ltd. owned 0.54% of Teva Pharmaceutical Industries worth $133,662,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Captrust Financial Advisors increased its position in shares of Teva Pharmaceutical Industries by 48.4% in the third quarter. Captrust Financial Advisors now owns 15,786 shares of the company's stock worth $284,000 after acquiring an additional 5,146 shares in the last quarter. HighTower Advisors LLC raised its position in Teva Pharmaceutical Industries by 461.8% in the third quarter. HighTower Advisors LLC now owns 148,605 shares of the company's stock valued at $2,675,000 after purchasing an additional 122,154 shares during the period. Quantinno Capital Management LP lifted its stake in shares of Teva Pharmaceutical Industries by 34.5% during the third quarter. Quantinno Capital Management LP now owns 36,145 shares of the company's stock worth $651,000 after purchasing an additional 9,269 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after buying an additional 23,283 shares in the last quarter. Finally, Orion Portfolio Solutions LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $198,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on TEVA shares. Bank of America lowered their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Finally, UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Up 1.3 %

Teva Pharmaceutical Industries stock traded up $0.18 during midday trading on Friday, hitting $13.61. The stock had a trading volume of 8,836,138 shares, compared to its average volume of 9,899,841. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The business has a fifty day moving average price of $15.51 and a 200 day moving average price of $17.70. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The stock has a market cap of $15.43 billion, a P/E ratio of -9.38, a P/E/G ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.